Xin Lang Cai Jing·2026-02-27 00:10Core Viewpoint - The domestic blood products industry is expected to maintain steady growth in the issuance of batches for albumin, intravenous immunoglobulin (IVIG), and fibrinogen by 2025, with an increase in the proportion of domestic albumin batch issuances compared to the previous year [1] Industry Summary - The issuance growth rate for factor VIII and prothrombin complex concentrate (PCC) is accelerating, while the issuance of rabies immunoglobulin and anti-rabies immunoglobulin is also showing good growth [1] - Due to centralized procurement and other factors, some domestic companies have adjusted the bidding prices for products like albumin and factor VIII, which is beneficial for increasing sales volume through price adjustments [1] - Companies are continuously advancing their research and development pipelines, focusing on recombinant products and new types of immunoglobulins, including chromatographic IVIG and subcutaneous immunoglobulin [1] - By 2026, the industry is advised to pay attention to the expansion of plasma stations, trends in industry mergers and acquisitions, and progress in new product development [1] - Companies that are at the forefront of the industry and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]